1. Home
  2. JANX vs CTRI Comparison

JANX vs CTRI Comparison

Compare JANX & CTRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JANX
  • CTRI
  • Stock Information
  • Founded
  • JANX 2017
  • CTRI 1909
  • Country
  • JANX United States
  • CTRI United States
  • Employees
  • JANX N/A
  • CTRI N/A
  • Industry
  • JANX Biotechnology: Pharmaceutical Preparations
  • CTRI
  • Sector
  • JANX Health Care
  • CTRI
  • Exchange
  • JANX Nasdaq
  • CTRI Nasdaq
  • Market Cap
  • JANX 1.6B
  • CTRI 1.8B
  • IPO Year
  • JANX 2021
  • CTRI 2024
  • Fundamental
  • Price
  • JANX $31.05
  • CTRI $18.55
  • Analyst Decision
  • JANX Strong Buy
  • CTRI Hold
  • Analyst Count
  • JANX 7
  • CTRI 7
  • Target Price
  • JANX $94.29
  • CTRI $19.00
  • AVG Volume (30 Days)
  • JANX 975.8K
  • CTRI 263.2K
  • Earning Date
  • JANX 05-06-2025
  • CTRI 05-07-2025
  • Dividend Yield
  • JANX N/A
  • CTRI N/A
  • EPS Growth
  • JANX N/A
  • CTRI N/A
  • EPS
  • JANX N/A
  • CTRI N/A
  • Revenue
  • JANX $10,588,000.00
  • CTRI $2,637,229,000.00
  • Revenue This Year
  • JANX N/A
  • CTRI $4.12
  • Revenue Next Year
  • JANX $250.58
  • CTRI $4.84
  • P/E Ratio
  • JANX N/A
  • CTRI N/A
  • Revenue Growth
  • JANX 30.99
  • CTRI N/A
  • 52 Week Low
  • JANX $22.52
  • CTRI $14.46
  • 52 Week High
  • JANX $71.71
  • CTRI $28.65
  • Technical
  • Relative Strength Index (RSI)
  • JANX 55.36
  • CTRI N/A
  • Support Level
  • JANX $27.93
  • CTRI N/A
  • Resistance Level
  • JANX $32.59
  • CTRI N/A
  • Average True Range (ATR)
  • JANX 1.97
  • CTRI 0.00
  • MACD
  • JANX 0.74
  • CTRI 0.00
  • Stochastic Oscillator
  • JANX 84.75
  • CTRI 0.00

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

About CTRI Centuri Holdings Inc. Common Stock

Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings primarily consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. They operate under two primary lines of business which includes Gas Utility Services and Electric Utility Services it is also their two reportable segments as well.

Share on Social Networks: